These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 7515847

  • 1. Site-directed primary in vitro immunization: production of HIV-1 neutralizing human monoclonal antibodies from lymphocytes obtained from seronegative donors.
    Chin LT, Hinkula J, Levi M, Ohlin M, Wahren B, Borrebaeck CA.
    Immunology; 1994 Mar; 81(3):428-34. PubMed ID: 7515847
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Human monoclonal antibodies against a recombinant HIV envelope antigen produced by primary in vitro immunization. Characterization and epitope mapping.
    Ohlin M, Broliden PA, Danielsson L, Wahren B, Rosen J, Jondal M, Borrebaeck CA.
    Immunology; 1989 Nov; 68(3):325-31. PubMed ID: 2480328
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD, Pendleton CD, Dunlop N, Minassian A, Nara PL, Berzofsky JA.
    J Immunol; 1993 Jun 15; 150(12):5647-65. PubMed ID: 8515081
    [Abstract] [Full Text] [Related]

  • 7. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.
    Haynes BF, Torres JV, Langlois AJ, Bolognesi DP, Gardner MB, Palker TJ, Scearce RM, Jones DM, Moody MA, McDanal C.
    J Immunol; 1993 Aug 01; 151(3):1646-53. PubMed ID: 8335949
    [Abstract] [Full Text] [Related]

  • 8. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM, McKeating JA, de Souza JB, Roitt IM, Delves PJ, Lund T.
    Virology; 1998 Nov 10; 251(1):59-70. PubMed ID: 9813203
    [Abstract] [Full Text] [Related]

  • 9. The CBD1 peptide corresponding to the caveolin-1 binding domain of HIV-1 glycoprotein gp41 elicits neutralizing antibodies in cynomolgus macaques when administered with the tetanus T helper epitope.
    Benferhat R, Martinon F, Krust B, Le Grand R, Hovanessian AG.
    Mol Immunol; 2009 Feb 10; 46(4):705-12. PubMed ID: 19010547
    [Abstract] [Full Text] [Related]

  • 10. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC, Stuber G, Wagner R, Wolf H, Modrow S.
    J Pept Sci; 1995 Feb 10; 1(2):109-23. PubMed ID: 9222988
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Specificity of humoral and cellular immune response against recombinant particles of nucleocapsid protein of human hepatitis B virus in rabbits.
    Isaguliants MG, Kadoshnikov YP, Kalinina TI, Smirnov VD, Wahren B.
    Biochemistry (Mosc); 1998 May 10; 63(5):551-8. PubMed ID: 9632891
    [Abstract] [Full Text] [Related]

  • 13. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
    Turbica I, Simon F, Besnier JM, LeJeune B, Choutet P, Goudeau A, Barin F.
    J Med Virol; 1997 Jul 10; 52(3):309-15. PubMed ID: 9210041
    [Abstract] [Full Text] [Related]

  • 14. Shared antigenic epitopes on the V3 loop of HIV-1 gp120 and proteins on activated human T cells.
    Trujillo JR, Rogers RA, Brain JD.
    Virology; 1998 Jun 20; 246(1):53-62. PubMed ID: 9656993
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY, Luo L, Wainberg MA, Li Y.
    Biol Chem; 1999 Mar 20; 380(3):353-64. PubMed ID: 10223338
    [Abstract] [Full Text] [Related]

  • 17. Primary in vitro immunization with multimeric synthetic peptides of HIV-1 envelope glycoproteins: generation of neutralizing human monoclonal antibodies.
    Fraisier C, Ebersold A, Blomberg J, Desgranges C.
    J Immunol Methods; 1994 Nov 10; 176(1):9-22. PubMed ID: 7963597
    [Abstract] [Full Text] [Related]

  • 18. Two new human monoclonal antibodies against HIV type 1 glycoprotein 120: characterization and neutralizing activities against HIV type 1 strains.
    Février M, Boudet F, Deslandres A, Theze J.
    AIDS Res Hum Retroviruses; 1995 Apr 10; 11(4):491-500. PubMed ID: 7543271
    [Abstract] [Full Text] [Related]

  • 19. Human CD4+ T cells can discriminate the molecular and structural context of T epitopes of HIV gp120 and HIV p66.
    Manca F, Fenoglio D, Valle MT, Li Pira G, Kunkl A, Ferraris A, Saverino D, Lancia F, Mortara L, Lozzi L.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul 01; 9(3):227-37. PubMed ID: 7540488
    [Abstract] [Full Text] [Related]

  • 20. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies.
    Baba E, Nakamura M, Ohkuma K, Kira J, Tanaka Y, Nakano S, Niho Y.
    J Immunol; 1995 Jan 01; 154(1):399-412. PubMed ID: 7527817
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.